Sign in

CIK 0001674416

  • Large accelerated filer

CRISPR Therapeutics AG

Sign in to watch
Ticker
CRSP
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
Switzerland
Entity type
Operating
EIN
473173478
Phone
+1 617-315-4600
Business address
BAARERSTRASSE 14, ZUG, Switzerland
Former names
CRISPR Therapeutics AG
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$4,881,673
in 7 filings, $1.5M under 10b5-1 plans

Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2023-02-21 Smith Brendan Chief Financial Officer Shares withheld for taxes −1,392 $48.26 $67K 5,072
2023-02-18 Smith Brendan Chief Financial Officer Exercise or conversion +3,825 6,464
2023-02-18 Smith Brendan Chief Financial Officer Exercise or conversion · Restricted Stock Units −3,825 11,475
2022-10-17 Smith Brendan Chief Financial Officer Shares withheld for taxes −1,111 $55.76 $62K 2,639
2022-10-14 Smith Brendan Chief Financial Officer Exercise or conversion +3,750 3,750
2022-10-14 Smith Brendan Chief Financial Officer Exercise or conversion · Restricted Stock Units +3,750 11,250
2022-10-07 Smith Brendan Chief Financial Officer Grant or award · Stock Option (Right to Buy) +14,000 14,000
2022-08-16 Smith Brendan Chief Financial Officer Grant or award · Restricted Stock Units +10,000 10,000
2022-02-18 Smith Brendan Chief Financial Officer Grant or award · Stock Option (Right to Buy) +30,000 30,000
2022-02-18 Smith Brendan Chief Financial Officer Grant or award · Restricted Stock Units +15,300 15,300
2021-10-14 Smith Brendan Chief Financial Officer Grant or award · Restricted Stock Units +15,000 15,000
2021-10-14 Smith Brendan Chief Financial Officer Grant or award · Stock Option (Right to Buy) +90,000 90,000

Page 1 of 1 · 12 trades